Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Mao J et al. | Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. | 2017 | Drug Metab. Rev. | pmid:27718639 |
Josephson F et al. | CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. | 2008 | Eur. J. Clin. Pharmacol. | pmid:18458892 |
Dutreix C et al. | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. | 2014 | Eur. J. Clin. Pharmacol. | pmid:24839948 |
Nylén H et al. | Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. | 2011 | Eur. J. Clin. Pharmacol. | pmid:21246351 |
Hole K et al. | Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. | 2017 | Eur. J. Clin. Pharmacol. | pmid:27975131 |
Lütjohann D et al. | 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. | 2009 | Int J Clin Pharmacol Ther | pmid:19954708 |
Pataj Z et al. | Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. | 2016 | J Chromatogr A | pmid:26607314 |
Yang Z and Rodrigues AD | Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? | 2010 | J Clin Pharmacol | pmid:20197489 |
Xu Y et al. | LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. | 2013 | J Pharm Biomed Anal | pmid:23948760 |
van de Merbel NC et al. | A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. | 2011 | J Pharm Biomed Anal | pmid:21507593 |